Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging therapies in multiple sclerosis.

Rachel Farrell1, Dominic Heaney, Gavin Giovannoni

  • 1Department of Neuroinflammation, Institute of Neurology, Queen Square, London, WC1N 3BG, UK. R.Farrell@ion.ucl.ac.uk

Expert Opinion on Emerging Drugs
|November 3, 2005
PubMed
Summary

New multiple sclerosis (MS) treatments focus on targeted therapies for inflammation, remyelination, and neuroprotection, aiming for greater efficacy than current options. While some novel drugs show promise, many are in early development, with mixed results in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does having bad epilepsy make you a good surgical candidate? A number needed to treat analysis.

Epilepsia open·2026
Same author

Syndrome-specific and familial imaging traits in juvenile absence epilepsy.

Epilepsia·2026
Same author

New valproate regulations, informed choice and seizure risk.

Journal of neurology·2024
Same author

Epilepsy & gambling: Risk factors for problem gambling behaviors in people with epilepsy.

Epilepsy & behavior : E&B·2021
Same author

Amyloidoma mimicking multiple sclerosis.

Practical neurology·2021
Same author

Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies: (Trends in Molecular Medicine, 26:3 p:296-310, 2020).

Trends in molecular medicine·2021

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a leading cause of neurological disability in young adults.
  • Current disease-modifying treatments like interferon-beta and glatiramer acetate offer modest benefits in disease progression and disability.
  • The need for more effective and targeted therapies for MS is critical.

Purpose of the Study:

  • To review emerging therapeutic strategies for multiple sclerosis (MS).
  • To explore novel treatments targeting MS pathophysiology, including inflammation, remyelination, and neuroprotection.
  • To assess the potential of new drug candidates and combination therapies for MS management.

Main Methods:

  • Review of current literature on MS pathophysiology and treatment development.

Related Experiment Videos

  • Analysis of novel therapeutic agents, including monoclonal antibodies, oral immunomodulators, and neuroprotective agents.
  • Evaluation of treatment efficacy based on clinical trial data and disease parameters.

    • Main Results:

    • Established treatments for MS show limited impact on long-term disability.
    • Emerging therapies target specific inflammatory pathways, neuroprotection, and remyelination.
    • New drug candidates like daclizumab, sirolimus, statins, NMDA antagonists, and Na+-channel blockers are under investigation.
    • Combination therapies are being explored for patients unresponsive to first-line treatments.

    Conclusions:

    • The development of selective MS therapies represents a significant advancement.
    • While many new treatments show potential, they are largely in early stages of development.
    • Further research and clinical trials are necessary to establish the efficacy and safety of novel MS therapies.